FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| OMB APPROVAL             |           |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name ar   | IDE  | 2. Issuer Name and Ticker or Trading Symbol  IDERA PHARMACEUTICALS, INC.  IDP ] |              |   |         |   |                             |      |   |  |        | all applicable) Director |   | 1     | g Person(s) to Issuer<br>10% Owner  |  |              |  |                       |   |
|--|--|---|--------------|---|---------|---|-----------------------------|------|---|--|--------|--------------------------|---|-------|---|--|--------------|--|-----------------------|---|
| (Last) (First) (Middle) 101 CHESTNUT STREET                                      |  |   |              |   |         | 3. Date of Earliest Transaction (Month/Day/Year) 04/05/2006 |                             |      |   |  |        |                          |   |       |   | Officer (give title below)   |              |  | Other (specify below) |   |
| (Street) BOSTON (City)   |  | <u> </u>  | 2108<br>Zip) |   | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |                             |      |   |  |        |                          |   |       | ne)<br><mark>X</mark> I   | ual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person |              |  |                       | son   |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |  |   |              |   |         |   |                             |      |   |  |        |                          |   |       |   |  |              |  |                       |   |
| 1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)                   |  |   |              |   | y/Year) | Execution Date,   |                             |      | Transaction Disposed (Code (Instr. and 5) |  |        |                          | ities Acquired (A<br>d Of (D) (Instr. 3 |       |   | Amou<br>ecuriti<br>enefici<br>wned   | ies<br>ially | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) |                       | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |  |   |              |   |         |   |                             |      | Code                                      | v  | Amount | (A<br>(D                 | .) or<br>)                              | Price | Repo<br>Trans   |  |              | (  |                       | (   |
| Common Stock 04/0  |  |   |              |   | .006    |   |                             |      | P   |  | 5,055  |                          | A                                       | \$0.5 | 44  | 4 789,782  |              | D  |                       |   |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |              |   |         |   |                             |      |   |  |        |                          |   |       |   |  |              |  |                       |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                              | 2. Conversion Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) Focurity (Month/Day/Year)                             |   |              | Fransaction Code (Instr. S) So AA (A Di of (In ar |         | sed<br>. 3, 4   | 6. Date Expiration (Month/D | n Da | Expiration                                | Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr<br>3 and 4) |        |                          | 1                                       |       | Number of derivative Securities Seneficially Dwned Following Reported Fransaction Instr. 4) | Owner<br>Form:<br>Direct<br>or Ind<br>(I) (Ins<br>4)   | (D)          | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)   |                       |   |

Explanation of Responses:

Remarks:

<u>Paul C. Zamecnik</u> <u>04/05/2006</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).